BioCryst Pharmaceuticals (BCRX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on BioCryst Pharmaceuticals (BCRX) is Neutral.

The composite score behind that read is +0.13, weighing +0.27 of bullish evidence against -0.17 bearish.

BioCryst Pharmaceuticals last closed at $8.55, +3.14% on the session.

Against the IVW growth benchmark the position is +2.34% over the forecast window.

The read is built from 15 underlying insights — 8 bullish and 7 bearish.

Agreement across those insights is 53%.

8 graded predictions for BCRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks BioCryst Pharmaceuticals in the 96th percentile on return on equity, where 100 is best.

BioCryst Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $2.12B.

StockMap tracks BioCryst Pharmaceuticals as the 84th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite BioCryst Pharmaceuticals ranks 33rd of 381 in the group, against a group median of -0.08.